secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001558370-23-017507
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Q3 cash $49.4M; uproleselan Phase 3 topline by Q2 2024; NDA filing by end 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $49.4M as of Sep 30, 2023; no revenue reported (pre-revenue biotech).
- Pivotal Phase 3 uproleselan topline results on track for end of Q2 2024; NDA filing expected by end 2024.
- Phase 1a GMI-1687 initial results expected by end of Q1 2024 as potential sickle cell disease treatment.
- R&D expenses $5.3M (up from $4.9M) driven by GMI-1687 trial; G&A expenses $4.5M (up from $3.8M).
- Updated uproleselan data in secondary AML to be presented at ASH December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/0001558370-23-017507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/glyc-20231103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer